TABLE 2.
Characteristics and outcomes of patients with implant-associated infections (n = 45)
| Variablef | Value |
|---|---|
| Age (yrs), mean (SD) | 64 (15) |
| Male sex, no. (%) | 24 (53.3) |
| Comorbidity, no. (%) | |
| Diabetes mellitus | 7 (15.5) |
| Rheumatoid arthritis | 3 (6.6) |
| Chronic renal failure | 5 (11.1) |
| Cancer | 5 (11.1) |
| COPD | 4 (8.8) |
| Liver cirrhosis | 2 (4.4) |
| Cardiac disease | 3 (6.6) |
| Type of implant, no. (%) | |
| Joint prosthesis | 26 (57.8) |
| Hip | 13 |
| Knee | 10 |
| Shoulder | 3 |
| Other implant | 19 (42.2) |
| Spine | 11 |
| Long bone | 5 |
| Other | 3 |
| Median (IQR) no. of days from implantation to infection diagnosis | 115 (27–424) |
| Fever, no. (%) | 13 (28.8) |
| Local signs of infection at admission, no. (%) | 31 (68.8) |
| Wound drainage, no. (%) | 21 +(46.6) |
| Fistula, no. (%) | 11 (24.4) |
| Median (IQR) leukocyte count (cells/mm3) | 7,300 (5,750–9,925) |
| Median (IQR) SCr (mg/dl) before dalbavancin treatmenta | 1 (0.6–1) |
| Median (IQR) highest SCr (mg/dl) during dalbavancina | 1 (0.6–1) |
| Baseline CRP (mg/dl)b | 5 (2.7–11.7) |
| Last control CRP (mg/dl)c | 1 (0.3–1.3) |
| Median (IQR) no. of days of antibiotics prior to dalbavancin treatment | 41 (21–87) |
| Reason for starting dalbavancin, no. (%) | |
| Failure to prior antibiotic | 12 (26.6) |
| Simplification | 23 (51.1) |
| Toxicity to prior antibiotic | 10 (22.2) |
| Median (IQR) no. of dalbavancin doses | 5 (3–8) |
| Other concomitant antibiotic, no. (%) | |
| Rifampin | 8 (17.7) |
| Other | 7 (15.5) |
| Outcome, no. (%)d | |
| Implant retention | 23 (52.3) |
| Success | 15 |
| Improvement | 8 |
| Failure | 0 |
| Implant removal | 21 (47.7) |
| Success | 16 |
| Improvement | 4 |
| Failure | 1 |
| Death, no. (%)e | 1 (2.2) |
| Median (IQR) no. of days of follow-up | 157 (75.5–273.5) |
a
Measured in 36 patients.
b
Measured in 42 patients.
c
Measured in 41 patients.
d
Evaluation from 44 cases. One case was lost during follow-up.
e
Not related to the infection.
f
COPD, chronic obstructive pulmonary disease; SCr, serum creatinine; CRP, C-reactive protein. No. (%), number (percent) of patients.